By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
NEW YORK (Reuters Health) – In patients with potentially resectable colorectal liver metastases, the use of combined PET and CT imaging (PET-CT) identifies those with occult extrahepatic disease…
Recent Videos in Reuters Health • The Doctor’s Channel Newscast Page 141
NEW YORK (Reuters Health) – For patients with multiple myeloma who are not eligible for autologous stem-cell transplantation, a four-drug combination regimen is promising. Adding thalidomide to bortezomib-melphalan-prednisone,…
NEW YORK (Reuters Health) – The GLP-1 receptor agonist exenatide used to treat type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) events, compared…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – The percentage of cardiac surgery patients given blood transfusions varies widely from center to center, but a conservative use of transfusions is not…
NEW YORK (Reuters Health) – Deep brain stimulation, of either the globus pallidus or subthalamic nuclei, can provide long-lasting improvement in motor symptoms in many patients with Parkinson’s…
NEW YORK (Reuters Health) – Patients with age-related macular degeneration treated with the anti-VEGF monoclonal antibodies bevacizumab and ranibizumab do not have any higher rates of mortality, MI…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – For women who have undergone laparoscopic surgery for severe endometriosis, ongoing chronic pelvic pain is relieved with use of the levonorgestrel-releasing intrauterine system…
NEW YORK (Reuters Health) – Mortality in acute coronary syndromes is no lower among those taking aspirin before the event than in non-aspirin users. This apparent “aspirin paradox”…
NEW YORK (Reuters Health) – There’s a 25% chance that patients with hypersensitivity to cephalosporins will also react to penicillins, a European group reports, but the risk with…
